Prolatan, eye drops 0.005% 2.5ml 3 pcs.

Latanoprost, an analogue of prostaglandin F2 alpha, is a selective FP receptor agonist and reduces intraocular pressure (IOP) by increasing aqueous outflow, mainly by uveoscleral route, as well as through the trabecular meshwork. IOP lowering starts approximately 3 – 4 hours after the drug injection, the maximum effect is observed after 8 – 12 hours and the action lasts for at least 24 hours.

It is established that latanoprost has no significant effect on aqueous humor production and on hemato-ophthalmic barrier.

When used in therapeutic doses latanoprost has no significant pharmacological effect on cardiovascular and respiratory systems.

Indications

Reduction of elevated intraocular pressure (IOP) in adults and children (over 1 year of age) with open-angle glaucoma or increased intraocular tone.

Note: In children under 3 years of age with primary congenital glaucoma, surgery (trabeculotomy/goniotomy) remains the first-line treatment.

Pharmacological effect

Latanoprost, a prostaglandin F2 alpha analogue, is a selective FP receptor agonist and reduces intraocular pressure (IOP) by increasing the outflow of aqueous humor, mainly through the uveoscleral pathway, but also through the trabecular meshwork. The decrease in IOP begins approximately 3–4 hours after administration of the drug, the maximum effect is observed after 8–12 hours, the effect persists for at least 24 hours.

It has been established that latanoprost does not have a significant effect on the production of aqueous humor and the blood-ophthalmic barrier.

When used in therapeutic doses, latanoprost does not have a significant pharmacological effect on the cardiovascular and respiratory systems.

Active ingredient

Latanoprost

Composition

1 ml contains:

Active substances:

latanoprost – 0.05 mg,

Excipients:

benzalkonium chloride – 0.2 mg,

sodium chloride – 4.1 mg,

disodium hydrogen phosphate anhydrous – 4.74 mg,

sodium dihydrogen phosphate monohydrate – 4.6 mg,

water for d/i – up to 1 ml.

Contraindications

Hypersensitivity to latanoprost or other components of the drug. Age up to 1 year (efficacy and safety have not been established).

With caution

Aphakia, pseudophakia with rupture of the posterior capsule of the lens, patients with known risk factors for macular edema (cases of the development of macular edema, including cystoid, have been described during treatment with latanoprost); inflammatory, neovascular or congenital glaucoma (due to lack of sufficient experience in using the drug); asthma; history of herpetic keratitis.

The use of Prolatan® should be avoided in patients with active herpetic keratitis and recurrent herpetic keratitis, especially associated with the use of prostaglandin analogues. Prolatan® should be used with caution in patients with risk factors for developing iritis/uveitis.

There is limited data on the use of Prolatan® in patients undergoing cataract surgery. In this regard, Prolatan® should be used with caution in this group of patients.

Side Effects

An increase in the number, length and thickness of eyelash hairs, darkening of the skin of the eyelids, changes in the color of the iris, iritis, uveitis, macular edema..
Blurred vision, discomfort in the eyes, redness of the conjunctiva, punctate epithelial keratopathy, swelling of the eyelids, crusts on the eyelids, photophobia, conjunctivitis, diplopia..
Retinal detachment, with diabetic retinopathy, hemorrhage into the vitreous body.
Respiratory tract infections, angina pectoris, muscle pain, heart rhythm disturbances..
Allergic reactions, rash…
Bronchial asthma, bronchospasm, shortness of breath.

Interaction

When two prostaglandin analogs are instilled into the eyes simultaneously, a paradoxical increase in IOP has been described, therefore the simultaneous use of two or more prostaglandins, their analogs or derivatives is not recommended.

Pharmaceutically incompatible with eye drops containing thiomersal – precipitation.

Overdose

An overdose of Prolatan solution is characterized by redness of the conjunctiva and episclera, nausea, abdominal pain, sweating, hot flashes, fatigue, dizziness.

If necessary, symptomatic therapy should be carried out.

Manufacturer

Sentiss Pharma Pvt.Ltd, India